BRPI0708912B8 - métodos in vitro para detecção de mycobacterium tuberculosis e de células t expressando cd8 que especificamente reconhecem seq id no: 11 em um indivíduo - Google Patents
métodos in vitro para detecção de mycobacterium tuberculosis e de células t expressando cd8 que especificamente reconhecem seq id no: 11 em um indivíduoInfo
- Publication number
- BRPI0708912B8 BRPI0708912B8 BRPI0708912A BRPI0708912A BRPI0708912B8 BR PI0708912 B8 BRPI0708912 B8 BR PI0708912B8 BR PI0708912 A BRPI0708912 A BR PI0708912A BR PI0708912 A BRPI0708912 A BR PI0708912A BR PI0708912 B8 BRPI0708912 B8 BR PI0708912B8
- Authority
- BR
- Brazil
- Prior art keywords
- cells
- detecting
- mycobacterium tuberculosis
- individual
- methods
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
métodos para detecção de uma infecção por mycobacterium tuberculosis. a presente invenção refere-se a métodos para detecção de uma infecção com mycobacterium tuberculosis (mtb) em um indivíduo que são descritos. os métodos incluem detecção da presença de células tcd8+ que especificamente reconhecem polipeptídio de mtb. os métodos incluem ensaios in vivo para detecção da presença de células t cd8+ em uma amostra biológica, e ensaios in vivo que detectam uma reação de hipersensibilidade do tipo retardado. os métodos podem também incluir detecção de polipeptídios e polinucleotídeos de mtb. reagentes para detecção de uma infecção por mtb são também descritos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78236406P | 2006-03-14 | 2006-03-14 | |
US60/782,364 | 2006-03-14 | ||
PCT/US2007/006534 WO2007106560A2 (en) | 2006-03-14 | 2007-03-14 | Methods for detecting a mycobacterium tuberculosis infection |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0708912A2 BRPI0708912A2 (pt) | 2011-06-14 |
BRPI0708912B1 BRPI0708912B1 (pt) | 2018-03-20 |
BRPI0708912B8 true BRPI0708912B8 (pt) | 2021-07-27 |
Family
ID=38208601
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0708865A BRPI0708865A8 (pt) | 2006-03-14 | 2007-03-14 | métodos para produzir uma resposta imune à tuberculose |
BRPI0708912A BRPI0708912B8 (pt) | 2006-03-14 | 2007-03-14 | métodos in vitro para detecção de mycobacterium tuberculosis e de células t expressando cd8 que especificamente reconhecem seq id no: 11 em um indivíduo |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0708865A BRPI0708865A8 (pt) | 2006-03-14 | 2007-03-14 | métodos para produzir uma resposta imune à tuberculose |
Country Status (7)
Country | Link |
---|---|
US (7) | US8053181B2 (pt) |
EP (13) | EP2441469A1 (pt) |
CN (1) | CN101438166A (pt) |
BR (2) | BRPI0708865A8 (pt) |
CA (1) | CA2649688A1 (pt) |
WO (2) | WO2007106536A2 (pt) |
ZA (2) | ZA200808644B (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60117164T2 (de) * | 2000-11-07 | 2006-08-03 | Immuno Vaccine Technologies Inc., Halifax | Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung |
EP2441469A1 (en) * | 2006-03-14 | 2012-04-18 | Oregon Health and Science University | Methods for producing an immune response to tuberculosis |
US8026076B2 (en) * | 2006-09-05 | 2011-09-27 | Hvidovre Hospital | IP-10 based immunological monitoring |
BRPI0604958B1 (pt) * | 2006-11-23 | 2022-05-17 | Fundação Oswaldo Cruz | Kit para distinção de mycobacterium tuberculosis, m. bovis, m. bovis bcg em uma amostra, e, método para distinguir mycobacterium tuberculosis, m. bovis, m. bovis bcg |
ES2588705T3 (es) | 2007-09-27 | 2016-11-04 | Immunovaccine Technologies Inc. | Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo |
US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
ES2524699T3 (es) | 2008-06-05 | 2014-12-11 | Immunovaccine Technologies Inc. | Composiciones que comprenden liposomas, un antígeno, un polinucleótido y un vehículo que comprende una fase continua de una sustancia hidrófoba |
AT506819B1 (de) * | 2008-06-12 | 2011-06-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzin zur behandlung von alzheimer-krankheit |
US8658350B2 (en) | 2008-09-22 | 2014-02-25 | Oregon Health & Science University | Methods for detecting Mycobacterium tuberculosis disease |
WO2011025742A1 (en) | 2009-08-28 | 2011-03-03 | Dow Global Technologies Inc. | Rotational molded articles, and method of making the same |
EP2501397B1 (en) * | 2009-11-20 | 2017-10-04 | Oregon Health and Science University | Methods for producing an immune response to tuberculosis |
US10105435B2 (en) | 2011-10-06 | 2018-10-23 | Immunovaccine Technologies Inc. | Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof |
WO2013090897A1 (en) * | 2011-12-15 | 2013-06-20 | The Trustees Of The University Of Pennsylvania | Using adaptive immunity to detect drug resistance |
CN103864907B (zh) * | 2012-12-18 | 2016-12-28 | 中国医学科学院病原生物学研究所 | 用于结核病诊断的蛋白以及试剂盒 |
CN104151411B (zh) * | 2013-05-14 | 2018-03-20 | 中国医学科学院病原生物学研究所 | 用于结核病诊断的蛋白以及药物组合物 |
TWI654200B (zh) | 2013-08-30 | 2019-03-21 | 環球免疫公司 | 治療或預防結核病的組合物及方法 |
US9970062B2 (en) | 2015-08-06 | 2018-05-15 | Roche Molecular Systems, Inc. | Compositions and methods for detection of mycobacterium tuberculosis |
CN107304231B (zh) * | 2016-04-18 | 2021-01-01 | 华中农业大学 | 一种结核分枝杆菌融合蛋白及应用 |
BR112019005732A2 (pt) * | 2016-09-22 | 2019-08-06 | Pace Diagnostics Inc | proteínas de mycobacterium tuberculosis em ensaios e dispositivos de diagnóstico para a detecção e o diagnóstico da tuberculose |
ES2950436T3 (es) | 2016-12-14 | 2023-10-10 | Becton Dickinson Co | Métodos y composiciones para obtener una valoración de tuberculosis en un sujeto |
CA3098015A1 (en) * | 2018-04-26 | 2019-10-31 | Children's National Medical Center | Mycobacterial antigen compositions and methods of use |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
CN112322566A (zh) * | 2020-11-17 | 2021-02-05 | 中国农业科学院北京畜牧兽医研究所 | 牛分枝杆菌弱毒株及其应用 |
Family Cites Families (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4444487A (en) | 1979-07-02 | 1984-04-24 | Xerox Corporation | Multiple-flash fuser |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4745055A (en) | 1985-05-07 | 1988-05-17 | California Biotechnology Inc. | Fused protein for enzyme immunoassay system |
US4895800A (en) | 1985-11-26 | 1990-01-23 | Phillips Petroleum Company | Yeast production of hepatitis B surface antigen |
US4811254A (en) | 1985-12-17 | 1989-03-07 | Nippon Gakki Seizo Kabushiki Kaisha | Displacement detector for an encoder |
US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
CA1340456C (en) | 1986-07-07 | 1999-03-23 | Hubert J.P. Schoemaker | Chimeric rodent/human immunoglobulins specific for tumor-associated antigens |
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
GB8626412D0 (en) | 1986-11-05 | 1986-12-03 | Clark M R | Antibodies |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
EP0278940A3 (en) | 1987-01-30 | 1988-12-07 | Smithkline Biologicals S.A. | Hepatitis b virus surface antigens and hybrid antigens containing them |
DE3789866T2 (de) | 1987-07-17 | 1994-09-22 | Rhein Biotech Proz & Prod Gmbh | DNA-Moleküle, die für FMDH-Kontrollabschnitte und Strukturgene für ein Protein mit FMDH-Aktivität kodieren, sowie deren Anwendung. |
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
DE10399031I1 (de) | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
CA1340203C (en) | 1987-09-16 | 1998-12-15 | Noboru Yanagida | Recombinant apivoxvirus |
AU622426B2 (en) | 1987-12-11 | 1992-04-09 | Abbott Laboratories | Assay using template-dependent nucleic acid probe reorganization |
JPH0630628B2 (ja) | 1987-12-16 | 1994-04-27 | キング醸造株式会社 | 生細胞数及び活力の測定方法 |
US4957795A (en) | 1988-05-13 | 1990-09-18 | Minnesota Mining And Manufacturing Company | Absorbent elastomeric wound dressing |
EP0425563B1 (en) | 1988-07-20 | 1996-05-15 | David Segev | Process for amplifying and detecting nucleic acid sequences |
US5093258A (en) | 1988-08-26 | 1992-03-03 | Therion Biologics Corporation | Recombinant fowlpox virus and recombination vector |
US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5188937A (en) | 1989-04-06 | 1993-02-23 | Becton, Dickinson And Company | Layered sandwich assay method for chlamydia and materials therefor |
US5270202A (en) | 1989-11-03 | 1993-12-14 | Syamal Raychaudhuri | Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen |
US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
US5427930A (en) | 1990-01-26 | 1995-06-27 | Abbott Laboratories | Amplification of target nucleic acids using gap filling ligase chain reaction |
GB9007024D0 (en) | 1990-03-29 | 1990-05-30 | Imperial College | Novel vaccine |
US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
WO1991019803A1 (en) | 1990-06-19 | 1991-12-26 | Applied Biotechnology, Incorporated | Self assembled, defective, nonself-propagating viral particles |
US5709860A (en) | 1991-07-25 | 1998-01-20 | Idec Pharmaceuticals Corporation | Induction of cytotoxic T-lymphocyte responses |
DK0596032T4 (da) | 1991-07-25 | 2004-07-26 | Idec Pharma Corp | Induktion af cytotoksiske T-lymfocytsvar |
US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
DE69311538D1 (de) | 1992-03-12 | 1997-07-17 | Alkermes Inc | Acth enthaltende mikrokugeln mit gesteuerter abgabe |
US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
US5662907A (en) | 1992-08-07 | 1997-09-02 | Cytel Corporation | Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes |
CA2142007C (en) | 1992-08-11 | 2007-10-30 | Robert Glen Urban | Immunomodulatory peptides |
FR2698877B1 (fr) | 1992-12-04 | 1995-04-07 | Atochem Elf Sa | Composition adhésives thermofusibles réticulables à l'humidité. |
US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
US6991797B2 (en) | 1993-07-02 | 2006-01-31 | Statens Serum Institut | M. tuberculosis antigens |
US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
US5648211A (en) | 1994-04-18 | 1997-07-15 | Becton, Dickinson And Company | Strand displacement amplification using thermophilic enzymes |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
WO1996002668A1 (en) | 1994-07-15 | 1996-02-01 | Azco Nobel N.V. | Use of rna polymerase to improve nucleic acid amplification process |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
CA2194761C (en) | 1994-07-15 | 2006-12-19 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6045802A (en) | 1994-10-03 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule |
EP1016418B1 (en) | 1994-10-03 | 2009-12-30 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Host cell comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule |
US5736524A (en) * | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
AT402203B (de) | 1995-06-13 | 1997-03-25 | Himmler Gottfried Dipl Ing Dr | Verfahren zur transkriptionsfreien amplifizierung von nucleinsäuren |
US6165460A (en) | 1995-07-10 | 2000-12-26 | Therion Biologics Corporation | Generation of immune responses to prostate-specific antigen (PSA) |
WO1998037919A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
AU740545B2 (en) * | 1997-04-02 | 2001-11-08 | Statens Serum Institut | Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis |
US7037510B2 (en) * | 1997-04-18 | 2006-05-02 | Statens Serum Institut | Hybrids of M. tuberculosis antigens |
EP1003531B1 (en) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
US6613881B1 (en) | 1997-05-20 | 2003-09-02 | Corixa Corporation | Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use |
US6555653B2 (en) * | 1997-05-20 | 2003-04-29 | Corixa Corporation | Compounds for diagnosis of tuberculosis and methods for their use |
CA2319380A1 (en) | 1997-11-10 | 1999-05-20 | Statens Serum Institut | Nucleic acid fragments and polypeptide fragments derived from m. tuberculosis |
EP1484405A1 (en) * | 1997-11-10 | 2004-12-08 | Statens Serum Institut | Nucleic acid fragments and polypeptide fragments derived from M. Tuberculosis |
ES2284247T3 (es) | 1998-04-03 | 2007-11-01 | University Of Iowa Research Foundation | Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos. |
US6294328B1 (en) * | 1998-06-24 | 2001-09-25 | The Institute For Genomic Research | DNA sequences for strain analysis in Mycobacterium tuberculosis |
US20020131976A1 (en) * | 1998-12-23 | 2002-09-19 | Ajit Lalvani | Tuberculosis vaccine |
ES2326257T3 (es) * | 1999-05-04 | 2009-10-06 | The University Of Medicine And Dentistry Of New Jersey | Proteinas expresadas por mycobacterium tuberculosis y no por bcg y su utilizacion como reactivos diagnosticos y vacunas. |
EP1218030A4 (en) | 1999-09-10 | 2004-09-15 | Univ Fordham | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF GRAFT REJECTS USING THERMAL SHOCK PROTEINS |
US6861513B2 (en) * | 2000-01-12 | 2005-03-01 | Schering Corporation | Everninomicin biosynthetic genes |
AU2001241738A1 (en) * | 2000-02-25 | 2001-09-03 | Corixa Corporation | Compounds and methods for diagnosis and immunotherapy of tuberculosis |
EP1268774A2 (en) | 2000-03-21 | 2003-01-02 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in prokaryotes |
US7657378B1 (en) * | 2000-03-30 | 2010-02-02 | Council Of Scientific & Industrial Research | Computer based method for identifying peptides useful as drug targets |
WO2001079257A2 (en) * | 2000-04-14 | 2001-10-25 | Phytera, Inc. | Multidrug resistance (mdr) efflux pump polypeptides |
KR100464485B1 (ko) | 2000-11-09 | 2004-12-31 | 엘지전자 주식회사 | 고속무선 패킷 데이터의 전송 장치 및 그 방법 |
CA2430896A1 (en) * | 2000-12-13 | 2002-06-20 | Argonex Pharmaceuticals, Inc. | Mhc class i associated peptides for prevention and treatment of tuberculosis |
AU2002306849A1 (en) * | 2001-03-21 | 2002-10-08 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in microorganisms |
FI116851B (fi) * | 2001-05-03 | 2006-03-15 | Fit Biotech Oyj Plc | Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita |
US7067492B2 (en) * | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
GB0124593D0 (en) * | 2001-10-12 | 2001-12-05 | Microbiological Res Authority | Mycobacterial antigens expressed under high oxygen tension |
US20040029129A1 (en) * | 2001-10-25 | 2004-02-12 | Liangsu Wang | Identification of essential genes in microorganisms |
US20050123511A1 (en) * | 2001-12-07 | 2005-06-09 | Mccreavy David T. | Dna vaccine |
WO2003066838A1 (en) * | 2002-02-08 | 2003-08-14 | The Director, All India Institute Of Medical Science | A process for identifying a novel target for use for the development of therapeutic modalities and drugs effective against tuberculosis |
US7074559B2 (en) * | 2002-03-06 | 2006-07-11 | Refents of the University of Minnesota | Mycobacterial diagnostics |
US20030236393A1 (en) * | 2002-03-22 | 2003-12-25 | United States Of America Dept Of Vetrans Affairs | Virulence genes of M. marinum and M. tuberculosis |
EP1523331B1 (en) * | 2002-07-13 | 2013-02-27 | Statens Serum Institut | Therapeutic tb vaccine |
US7364869B2 (en) * | 2003-07-29 | 2008-04-29 | The J. David Gladstone Institutes | Method of detecting antigen-specific T lymphocytes |
ITRM20030411A1 (it) * | 2003-08-29 | 2005-02-28 | Consiglio Nazionale Ricerche | Uso di sequenze geniche specifiche di mycobacterium tubercolosis ecorrispondenti proteine per la diagnosi e la prevenzione di infezione tubercolare. |
EP1518932A1 (en) * | 2003-09-29 | 2005-03-30 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Modified vaccinia virus Ankara (MVA) mutant and use thereof |
US7424370B2 (en) * | 2004-02-06 | 2008-09-09 | Council Of Scientific And Industrial Research | Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential |
GB0406271D0 (en) * | 2004-03-19 | 2004-04-21 | Isis Innovation | Diagnostic test |
US20090070897A1 (en) * | 2006-01-12 | 2009-03-12 | Goldman Barry S | Genes and uses for plant improvement |
US7566459B2 (en) * | 2005-02-28 | 2009-07-28 | New York University | Modified mycobacterium tuberculosis strains and uses thereof |
JP5164830B2 (ja) * | 2005-04-29 | 2013-03-21 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 結核菌感染の予防または治療のための新規方法 |
EP2305701A1 (en) | 2005-07-01 | 2011-04-06 | Forsyth Dental Infirmary for Children | Tuberculosis antigen detection assays and vaccines |
EP2441469A1 (en) | 2006-03-14 | 2012-04-18 | Oregon Health and Science University | Methods for producing an immune response to tuberculosis |
KR100756676B1 (ko) * | 2006-11-23 | 2007-09-07 | 제일모직주식회사 | 실리콘계 미립자, 그 제조 방법, 및 그 미립자가 함유된열가소성 수지 조성물 |
MX351247B (es) * | 2007-04-04 | 2017-10-05 | Infectious Disease Res Institute Star | Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos. |
WO2009039854A2 (en) * | 2007-09-27 | 2009-04-02 | Dako Denmark A/S | Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics |
MX2011000982A (es) * | 2008-07-25 | 2011-03-02 | Glaxosmithkline Biolog Sa | La proteina de tuberculosis rv2386c, composiciones y usos de la misma. |
AU2009273128A1 (en) * | 2008-07-25 | 2010-03-11 | All India Institute Of Medical Science | Constructing a DNA chimera for vaccine development against Leishmaniasis and tuberculosis |
US8658350B2 (en) * | 2008-09-22 | 2014-02-25 | Oregon Health & Science University | Methods for detecting Mycobacterium tuberculosis disease |
US10369204B2 (en) * | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
US8691502B2 (en) * | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
EP2501397B1 (en) * | 2009-11-20 | 2017-10-04 | Oregon Health and Science University | Methods for producing an immune response to tuberculosis |
US10703784B2 (en) * | 2011-09-30 | 2020-07-07 | La Jolla Institute For Allergy And Immunology | Antigens and epitopes derived from Mycobacterium tuberculosis |
-
2007
- 2007-03-14 EP EP11192866A patent/EP2441469A1/en not_active Withdrawn
- 2007-03-14 EP EP10150055.1A patent/EP2207035B1/en not_active Not-in-force
- 2007-03-14 WO PCT/US2007/006472 patent/WO2007106536A2/en active Application Filing
- 2007-03-14 BR BRPI0708865A patent/BRPI0708865A8/pt not_active Application Discontinuation
- 2007-03-14 EP EP11178711.5A patent/EP2397854B1/en not_active Not-in-force
- 2007-03-14 EP EP11178706.5A patent/EP2397853B1/en not_active Not-in-force
- 2007-03-14 EP EP07753122A patent/EP1994409A2/en not_active Withdrawn
- 2007-03-14 EP EP11178716.4A patent/EP2397856B1/en not_active Not-in-force
- 2007-03-14 US US12/282,862 patent/US8053181B2/en active Active
- 2007-03-14 BR BRPI0708912A patent/BRPI0708912B8/pt active IP Right Grant
- 2007-03-14 EP EP10171127.3A patent/EP2253957B1/en active Active
- 2007-03-14 EP EP11192874.3A patent/EP2441493B1/en active Active
- 2007-03-14 CA CA002649688A patent/CA2649688A1/en not_active Abandoned
- 2007-03-14 WO PCT/US2007/006534 patent/WO2007106560A2/en active Application Filing
- 2007-03-14 US US12/282,865 patent/US7842299B2/en active Active
- 2007-03-14 EP EP11178714A patent/EP2397855A3/en not_active Withdrawn
- 2007-03-14 EP EP07753181A patent/EP2005184A2/en not_active Withdrawn
- 2007-03-14 EP EP11192868.5A patent/EP2441470B1/en active Active
- 2007-03-14 EP EP11178704.0A patent/EP2397852B1/en not_active Not-in-force
- 2007-03-14 EP EP11178719.8A patent/EP2428801B1/en active Active
- 2007-03-14 CN CNA2007800166607A patent/CN101438166A/zh active Pending
-
2008
- 2008-10-09 ZA ZA2008/08644A patent/ZA200808644B/en unknown
- 2008-10-09 ZA ZA2008/08643A patent/ZA200808643B/en unknown
-
2010
- 2010-09-29 US US12/894,051 patent/US8101192B2/en active Active
-
2011
- 2011-09-23 US US13/244,126 patent/US8361707B2/en active Active
- 2011-12-20 US US13/332,150 patent/US8440206B2/en active Active
-
2012
- 2012-12-18 US US13/719,124 patent/US9040233B2/en active Active
-
2015
- 2015-04-22 US US14/693,609 patent/US20150219645A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0708912B8 (pt) | métodos in vitro para detecção de mycobacterium tuberculosis e de células t expressando cd8 que especificamente reconhecem seq id no: 11 em um indivíduo | |
BR112012021202A2 (pt) | aparelho e metodos para preparacao, reacao e deteccao integradas de amostras | |
MX337666B (es) | Ensayos regulados mediante proximidad para detectar proteinas de fusion oncogenicas. | |
ES2570731T3 (es) | Método de detección de cáncer | |
WO2011063283A3 (en) | Methods for detecting a mycobacterium tuberculosis infection | |
MX2010009766A (es) | Ensayo de proteasa. | |
WO2008119081A8 (en) | System and method for high resolution analysis of nucleic acids to detect sequence variations | |
PE20120616A1 (es) | Sondas y cebadores para la deteccion de chikungunya | |
BR112012020251A2 (pt) | dispositivo de análise para a aquisição de amostra, tratamento e reação | |
CO6511214A2 (es) | Detección del evento das 40278 9 de aad 1 | |
TW200720441A (en) | New labelling strategies for the sensitive detection of analytes | |
EP2031376A3 (en) | Assay device with shared zones | |
WO2008094902A3 (en) | Compositions and methods for the detection of a nucleic acid using a cleavage reaction | |
BR112012018394B8 (pt) | método para detecção de uma sequência de ácido nucleico alvo e kit para detecção de uma sequência de ácido nucleico alvo | |
WO2010108095A3 (en) | Microfluidic cell motility assay | |
WO2011069029A3 (en) | Lateral flow assays | |
WO2007133586A3 (en) | Systems and methods for developing diagnostic tests based on biomarker information from legacy clinical sample sets | |
DK2038430T3 (da) | Toll-Like-Receptor-4-dysfunktion og de biologiske anvendelser deraf | |
ES2638294T3 (es) | Método de detección de cáncer | |
ATE526583T1 (de) | Immunomagnetische erfassung und abbildung biologischer zielmoleküle | |
EA201200907A1 (ru) | Способ обнаружения генетического материала chlamydia trachomatis, зонд нуклеиновой кислоты (варианты), прямой (варианты) и обратный (варианты) праймеры пцр, их содержащий компонент пцр, содержащий вышеуказанный компонент набор и способ обнаружения генетического материала pectobacterium atrosepticium | |
BR112014020513A2 (pt) | Métodos e sistemas para amplificação de sinal de bioensaios | |
FR2900936B1 (fr) | Procede et methodes de detection de la maladie d'alzheimer | |
BR112017011545A2 (pt) | ensaio de desvio de mobilidade homogênea indireto para a detecção de produtos biológicos nas amostras do paciente | |
GB0506183D0 (en) | Antigen detection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06H | Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette] |
Free format text: REF. A RPI NO 2155 DE 24/04/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO. |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] | ||
B07A | Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/03/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO |